Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection
Open Access
- 12 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (12), 1879-1885
- https://doi.org/10.1093/infdis/jir661
Abstract
Background. Antibody to influenza virus hemagglutinin has been traditionally associated with protection. Questions have been raised about its use as a surrogate for vaccine efficacy, particularly with regard to an absolute titer indicating seroprotection.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine FailuresThe Journal of Infectious Diseases, 2011
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Seasonal influenza vaccines: evolutions and future trendsExpert Review of Vaccines, 2009
- FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007Vaccine, 2008
- A Framework for Assessing Immunological Correlates of Protection in Vaccine TrialsThe Journal of Infectious Diseases, 2007
- Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young ChildrenNew England Journal of Medicine, 2007
- Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated VaccinesNew England Journal of Medicine, 2006
- Immunogenicity and protective efficacy of influenza vaccinationVirus Research, 2004
- The influenza vaccine licensing processVaccine, 2003
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972